Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients
Clinical trial NCT06888856 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06888856
- Sponsor
- Tel-Aviv Sourasky Medical Center
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-03-19
- Primary completion
- 2030-03-03
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.